Core Insights - Xeris Biopharma reported $54.27 million in revenue for Q3 2024, marking a 12.3% year-over-year increase and a 5.09% surprise over the Zacks Consensus Estimate of $51.64 million [1] - The company posted an EPS of -$0.06, which is an improvement from -$0.09 a year ago, resulting in a 33.33% EPS surprise compared to the consensus estimate [1] Revenue Breakdown - Gvoke product revenue was $22.94 million, slightly below the estimated $22.97 million [3] - Keveyis product revenue reached $12.19 million, compared to the estimated $12.50 million [3] - Recorlev product revenue was $17.73 million, exceeding the estimated $15.07 million [3] - Total net product revenue was $52.86 million, surpassing the estimated $50.53 million [3] - Revenue from royalties, contracts, and other sources was $1.41 million, exceeding the estimated $0.93 million [3] Stock Performance - Xeris Biopharma shares have increased by 20.9% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.9% [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]

Group 1 - Xeris Biopharma reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of 33.33% [1] - The company posted revenues of $54.27 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 5.09%, and showing an increase from $48.32 million year-over-year [2] - Xeris Biopharma shares have increased approximately 43% since the beginning of the year, outperforming the S&P 500's gain of 25.2% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $52.86 million, and for the current fiscal year, it is -$0.40 on revenues of $193.2 million [7] - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8]

Financial Performance - Total revenue for Q3 2024 reached a record $54.3 million, with product revenue of $52.9 million, marking a 27% increase year-over-year and a 14% increase quarter-over-quarter[1][2] - Gvoke® net revenue was $22.9 million, a 29% increase compared to Q3 2023, with prescriptions exceeding 70,000, growing 20% year-over-year[4] - Recorlev® net revenue was $17.7 million, representing a 119% increase year-over-year, driven by a 125% increase in the average number of patients on therapy[4] - Total revenue for the nine months ended September 30, 2024, reached $142,971,000, compared to $119,524,000 for the same period in 2023, reflecting a year-over-year increase of 19.6%[14] - The net loss for the three months ended September 30, 2024, was $15,738,000, compared to a net loss of $12,189,000 for the same period in 2023, indicating a 29% increase in losses[14] Guidance and Projections - The company raised its full-year revenue guidance to $198 million - $202 million, up from the previous guidance of $190 million - $200 million[1][2] - The company is focused on maintaining over 20% product revenue growth and advancing its pipeline, including the Phase 3 ready XP-8121[2] Expenses and Losses - Net loss for Q3 2024 was $15.7 million, or ($0.11) per share, with adjusted earnings per share of ($0.06) after excluding CEO succession plan costs[6] - Total operating expenses remained relatively flat compared to the previous quarter when excluding non-routine charges, indicating effective cost management[2] - Research and development expenses increased by $0.9 million for Q3 2024, primarily due to higher spending on pipeline and personnel-related expenses[6] - Selling, general and administrative expenses for the three months ended September 30, 2024, were $44,969,000, compared to $37,287,000 in the same period last year, reflecting a 20.7% increase[14] - Research and development expenses for the nine months ended September 30, 2024, were $19,468,000, up from $15,959,000 in the prior year, marking a 22.5% increase[14] Assets and Liabilities - Total cash, cash equivalents, and short-term investments at the end of Q3 2024 were $69.4 million, down from $72.5 million at the end of 2023[7] - Total current assets as of September 30, 2024, amounted to $162,799,000, up from $156,264,000 at the end of 2023, showing a growth of 4.3%[15] - Cash and cash equivalents decreased to $59,232,000 from $67,449,000, a decline of 12.5%[15] - Total liabilities increased to $349,427,000 as of September 30, 2024, compared to $329,384,000 at the end of 2023, representing a rise of 6.1%[15] Operational Losses - The company reported a loss from operations of $12,893,000 for the three months ended September 30, 2024, compared to a loss of $4,913,000 in the same period last year[14] Pipeline and Development - Xeris has a robust pipeline of development programs aimed at extending current marketed products and introducing new products using proprietary formulation technology platforms[10] - Product revenue for the three months ended September 30, 2024, was $52,861,000, an increase from $41,697,000 in the same period last year, representing a growth of 26%[14]

Editor's note: Seeking Alpha is proud to welcome PJ Research as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. I'm an Investment Officer specializing in private equity and venture capital, focused on cutting-edge sectors like deeptech, quantum technologies, biotechnology, pharmaceuticals, and the energy transition. My approach is to evaluate the addres ...

Core Insights - The article discusses the investment strategy of Compounding Healthcare, which utilizes data analytics, technical analysis, and clinical data to identify potential multi-bagger investments in the healthcare sector [1]. Group 1 - Compounding Healthcare has been actively managing a diverse healthcare portfolio, focusing on innovative companies that develop breakthrough therapies and pharmaceuticals [1]. - The leader of Compounding Healthcare has a background in the medical field and emphasizes the importance of catalysts for potential acquisitions in the biotech sector [1]. - The article indicates that it has been approximately seven months since the last analysis on Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), during which a conservative investment stance was adopted while awaiting a strong reversal setup [1].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter ...

Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven Pieper - CFO Allison Wey - SVP, IR and Corporate Communications Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Rohan Mathur - Oppenheimer Operator Hello, everyone, and welcome to today's Xeris Biopharma Second Quarter 2024 Financial Results Call. My name is Drew, a ...

Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.09%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.14, delivering a surprise of -16.67%. Over the last four quarters, the company has surpas ...

Exhibit 99.1 XERIS XERIS BIOPHARMA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period prior year Ended Q2 with $77.6M in cash, cash equivalents and short-term investments Tightens full-year 2024 guidance: total net revenue to $190M-$200M and year-end cash balance to $60M-$75M John Shannon appointed CEO and Kevin McCulloch promoted to President and COO per the Comp ...

From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a posit ...